Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. (ICPT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
icpt · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Intercept Pharmaceuticals, Inc. (ICPT) measures how much investors pay for each dollar of the company's trailing earnings. ICPT's current PE ratio of 5.58x is calculated by dividing its stock price of $19.00 by its TTM earnings per share of $3.41. +53.7% elevated vs 5Y avg 3.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2010 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Intercept Pharmaceuticals, Inc.You ICPT | $795M | 5.58x | — | $3.41 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 ASLAN Pharmaceuticals Limited ASLN | $777M | N/A | — | -$10.75 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Exscientia plc EXAI | $633M | N/A | — | -$1.18 |
 Gracell Biotechnologies Inc. GRCL | $198M | N/A | — | -$44.87 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | 3.63x | $3.41 | — | |
2021-12-31 FY2021 | — | $-4.55 | — | |
2020-12-31 FY2020 | — | $-9.83 | — | |
2019-12-31 FY2019 | — | $-12.35 | — | |
2018-12-31 FY2018 | — | $-10.86 | — | |
2017-12-31 FY2017 | — | $-14.38 | — | |
2016-12-31 FY2016 | — | $-16.74 | — | |
2015-12-31 FY2015 | — | $-9.56 | — | |
2014-12-31 FY2014 | — | $-13.63 | — | |
2013-12-31 FY2013 | — | $-3.76 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Intercept Pharmaceuticals, Inc. (ICPT) measures how much investors pay for each dollar of the company's trailing earnings. ICPT's current PE ratio of 5.58x is calculated by dividing its stock price of $19.00 by its TTM earnings per share of $3.41.
Frequently asked questions
ICPT pe ratio · 6 questionsICPT's current PE ratio is 5.58x as of 2026-06-09, based on a stock price of $19.00 and TTM EPS of $3.41. Data sourced from Financial Modeling Prep via ICPT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Intercept Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09